Medical News

RSS

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.

30 Aug 2010

Health IT: New Medicaid rules, a race for meaningful use, fraud prevention

Instructions for state Medicaid directors to distribute some of the funding for electronic medical records through their programs beginning next year have been circulated by the federal Centers for Medicare & Medicaid Services, American Medical News reports. "The incentive program stipulates that the federal government will pay the full cost of Medicaid bonuses to eligible physicians who adopt certified EMR technology in a way that meets the government's 'meaningful use' criteria.

30 Aug 2010

XIFIN ranked #1,447th on Inc. 5000 list of fastest-growing private companies

XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, today announced that the company has been named to the 2010 Inc. 5000 list of fastest-growing private companies for the fourth consecutive year, ranking 1,447th. The company ranked No. 96 in Top Software Companies, and No. 34 in Top Companies in the San Diego Metro Area. The list is widely regarded to include the most innovative and entrepreneurial companies in the nation.

30 Aug 2010

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

30 Aug 2010

AMA supports recommended medical loss ratio rules

The American Medical Association and state medical societies are supporting a proposal by the National Association of Insurance Commissioners on what expenditures insurers can consider medical spending under the new health law.

30 Aug 2010

Lineagen completes $10.8 million Series A financing

Lineagen, Inc., a developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders and others, today announced that PrairieGold Venture Partners has joined Lineagen's existing institutional venture investors in a further $5 million closing of its Series A round, which completes Lineagen's $10.8 million Series A financing.

30 Aug 2010

Perfadex improves survival in lung tranplant patients: Study

A recently published study in The Journal of Heart and Lung Transplantation shows that the patients who are most seriously ill before lung tranplantation have better one-year survival when Perfadex is used as the preservation solution for donor lungs compared with UW solution. Furthermore, the patients who received lungs preserved in Perfadex ran a significantly lower risk of being affected by rejection reactions requiring treatment.

30 Aug 2010

HealthInfoNet partners with HLI to implement HIE statewide

HealthInfoNet, the nonprofit organization managing the Health Information Exchange for the State of Maine, today announced that it is partnering with Health Language, Inc., the global leader in medical terminology management, as it transitions from a two-year demonstration project to a full statewide HIE implementation. Health Language will support the Maine HIE's clinical content integration strategy during this expansion.

30 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Positron Corporation is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology annual meeting, September 23-26 in Philadelphia, PA.

30 Aug 2010

AMS enters 10-year contract to supply radiation therapy services at Hospital Santa Paula, Brazil

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a ten-year contract to supply radiation therapy services at Hospital Santa Paula (HSP) in São Paulo, Brazil. AMS will place an advanced technology linear accelerator with IMRT capabilities at HSP, and is expected to begin treating patients in early 2012 in conjunction with the expected completion of a new comprehensive cancer center to be built by the hospital.

30 Aug 2010

Emdeon Commercial MedRx solution launched to make commercial medical claims process efficient

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced the launch of Emdeon Commercial MedRx, a specialized processing solution that enables retail pharmacies to submit commercial medical claims electronically to medical payers and health plans across the U.S.

30 Aug 2010

Otonomy announces closing of $38.5 million Series B financing

Otonomy, Inc. announced today that it has closed a $38.5 million Series B financing co-led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech. This financing is incremental to the $10 million Series A closed with Avalon Ventures in June 2010. Avalon also participated in the Series B round.

30 Aug 2010

SearchAmerica announces launch of Data Breach Advance Response for hospitals

SearchAmerica®, a part of Experian® and a leader in financial clearing services for health care, today launched its newest service offering for hospitals, Data Breach Advance Response™. The new service helps hospitals by providing a data breach preparedness plan so they can respond quickly and efficiently should a breach occur.

30 Aug 2010

TDWI recognizes CRI as 2010 Best Practices Award Winner

QlikTech today announced that its customer, Centerstone Research Institute, has been recognized as a 2010 Best Practices Award Winner by The Data Warehousing Institute.

30 Aug 2010

Aptus Endosystems announces completion of $15M Series AA financing

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair, announced the completion of a $15 million Series AA financing. U.S. Venture Partners and Longitude Capital led the round in continuation of their commitment to Aptus' innovative technologies for the treatment of aortic aneurysms.

30 Aug 2010

West Physics Consulting ranked #2230 on fourth annual Inc. 5000 list

Inc. magazine has ranked West Physics Consulting, LLC No. 2230 on its fourth annual Inc. 5000 list, an exclusive ranking of the nation's fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy -- America's independent-minded entrepreneurs. Music website Pandora, convenience store chain 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of the iconic children's red wagon, are among the prominent brands featured on this year's list.

30 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

IriSys signs business alliance agreement with Xcelience

IriSys and Xcelience have entered into a business alliance agreement to advance the ability to streamline access to CMC and regulatory expertise for North American pharmaceutical and biotechnology companies.

30 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010